Bulletin from Sobi's Extraordinary General Meeting (EGM)

Sobi Sobi Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees acrossEurope,North America, theMiddle East,AsiaandAustralia. In 2023, revenue amounted toSEK 22.1 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at...

STOCKHOLM, 11/12/2024 (informazione.news - comunicati stampa - salute e benessere)

Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe , North America , the Middle East , Asia and Australia . In 2023, revenue amounted to SEK 22.1 billion . Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

Gerard Tobin
Head of Communications and Investor Relations

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/bulletin-from-sobi-s-extraordinary-general-meeting--egm-,c4080180

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/bulletin-from-sobis-extraordinary-general-meeting-egm-302328761.html